Close Menu

NEW YORK – The US Food and Drug Administration on Friday approved lisocabtagene maraleucel (Bristol Myers Squibb's Breyanzi) as a treatment for relapsed or refractory large B-cell lymphoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.